This study aims to systematically evaluate the efficacy and safety of CD38-targeted monoclonal antibodies compared with those of standard regimens.<h4>Methods</h4>This study searched PubMed, the Cochrane Library, Web of Science, and Embase from inception until 30 June 2025 for randomized controlled trials (RCTs) comparing CD38 antibodies (alone or in combination) with proteasome inhibitor- or immunomodulatory agent-based control regimens in adults with multiple myeloma. Here, CD38 is linked to plasma cell myeloma.